Eli Lilly, in collaboration with the FDA, has granted access to its promising obesity treatment, retatrutide, to a single individual through the agency’s compassionate use program. This decision underscores the urgency and potential of the drug, which is currently under investigation for its efficacy in weight management.
The compassionate use program allows patients with serious or life-threatening conditions to access investigational therapies outside of clinical trials, reflecting a growing trend in the pharmaceutical industry to prioritize patient needs. This particular case raises questions about the criteria for such access and the implications for future regulatory practices, especially as the demand for innovative obesity treatments continues to rise.
As the landscape of drug development evolves, the implications of this decision may influence how other companies approach compassionate use requests, potentially setting precedents for patient access to breakthrough therapies in the pipeline.
Use the database as your supply chain compass →
